FLAMSA

FLAMSA is a sequential chemotherapy regimen used primarily as a cytoreductive induction therapy for patients with high-risk acute myeloid leukemia (AML) or advanced myelodysplastic syndrome (MDS) prior to allogeneic hematopoietic stem cell transplantation (HSCT). The regimen consists of fludarabine phosphate, amsacrine, and cytarabine (Ara-C). It is designed to achieve rapid debulking of leukemic cells in patients with refractory or relapsed disease, serving as a bridge to transplant. Typically, the FLAMSA induction is followed by a reduced-intensity conditioning (RIC) regimen, such as fludarabine, cyclophosphamide, and total body irradiation (TBI), to provide immunosuppression and further antileukemic activity before stem cell infusion. This approach aims to improve event-free survival in high-risk populations while minimizing the toxicity associated with traditional high-dose conditioning.

Other names

fludarabine + amsacrine + cytarabineFLAMSA regimen